z-logo
Premium
Fetal pulmonary artery Doppler evaluation in pregnant women after recovery from COVID‐19
Author(s) -
Turgut Ezgi,
Ayhan Sule Goncu,
Oluklu Deniz,
Tokalioglu Eda Ozden,
Tekin Ozlem Moraloglu,
Sahin Dilek
Publication year - 2021
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.13916
Subject(s) - medicine , pulmonary artery , fetus , acceleration time , covid-19 , cardiology , prospective cohort study , lung , pregnancy , obstetrics , disease , acceleration , genetics , physics , classical mechanics , infectious disease (medical specialty) , biology
Abstract Objective To evaluate fetal lung development using pulmonary artery Doppler in pregnant women who had recovered from COVID‐19. Methods The prospective case–control study included 41 pregnant women who had recovered from COVID‐19 and 43 healthy pregnant women (control group). All the women in the study group had been diagnosed with COVID‐19 and had completed a quarantine period. Results The demographic data of patients were similar in the groups ( P  > 0.05). Main pulmonary artery peak systolic velocity was higher and pulsatility indices were lower in pregnant women who recovered from COVID‐19 compared to the controls ( P  < 0.001, P  = 0.001). Acceleration time, ejection time, and acceleration/ejection time ratio (PATET) of the fetal MPA Doppler were significantly decreased in pregnant women who recovered from COVID‐19 ( P  < 0.001, P  = 0.036, and P  = 0.002, respectively). The patients who had recovered from COVID‐19 were divided into two groups: those treated with expectant management and those treated in hospital. The pulmonary artery acceleration time and PATET ratio were significantly lower in the group treated in the hospital ( P  = 0.023 and P  = 0.045, respectively). Conclusion Detailed Doppler evaluations of the pulmonary artery may help in evaluating the fetal adverse effects of COVID‐19 disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here